IM Cannabis Corp (IMCC)

Introduction

IM Cannabis Corp is a Nasdaq-listed (NASDAQ: IMCC) medical cannabis company with operations in Israel and Germany. Founded over a decade ago and approved by the Israeli Ministry of Health, IMC supplies cannabis products to medical patients through a vertically integrated ecosystem encompassing cultivation, distribution, and retail.

Corporate Structure

• Employee Count: 201–500 (LinkedIn)
• Primary Markets:
  • Israel (via Focus Medical Herbs Ltd.)
  • Germany (via Adjupharm GmbH, EU-GMP certified)
• Canadian Operations: Discontinued as of May 2025; assets divested
• Supply Chain: Globally sourced, data-driven approach supporting research and development as well as patient insights
• Distribution Channels:
  • Retail pharmacies
  • Online platforms
  • Logistics hubs

Developments and News

• May 28, 2025: IMC filed for voluntary delisting of its common shares from the Canadian Securities Exchange (CSE).
• June 2, 2025: Final trading day on the CSE; shares continue trading on Nasdaq under “IMCC.”
• August 12–18, 2025: Scheduled earnings release window.
• Strategic Pivot: Exited the Canadian market to reallocate resources toward Israel and Germany, identified as the company's primary markets.

Financial and Strategic Analysis

Metric	Value
Share Price (June 2, 2025)	USD 3.92
Price Change (1-Day)	–36.77%
Volume (June 2, 2025)	1,923,803
Market Cap (intraday)	USD 12.1 M
52-Week Range	USD 1.29 – 7.12
Revenue (TTM)	USD 54.5 M
Net Income (TTM)	–USD 4.69 M
Profit Margin	–8.6%
Return on Equity (TTM)	–96.8%
Price/Sales (TTM)	0.48
Price/Book (MRQ)	4.96
Total Cash (MRQ)	USD 1.39 M
Total Debt/Equity (MRQ)	497.3%
Beta (5Y Monthly)	3.17

• Liquidity: Average daily volume (3,878,222 on Yahoo Finance) supports active trading on Nasdaq.
• Leverage: High debt-to-equity ratio reflects financing for infrastructure expansion in Europe.
• Profitability: Negative margins and return on equity indicate ongoing investment in market development and product supply chain.

Market Position and Industry Context

• Israel: Established regulatory framework; IMC leverages its Ministry of Health approval and data insights to supply medical strains.
• Germany: Growing medical cannabis market; IMC’s EU-GMP packing facility and GDP logistics center serve pharmacies and other clients.
• Competition: Other licensed European suppliers; IMC differentiates through vertically integrated operations and proprietary patient data.
• Regulatory Environment: Strict quality and compliance standards in both Israel and the EU create barriers to entry and reinforce IMC’s certified infrastructure.

TL;DR

As of June 2, 2025, IM Cannabis Corp shares trade exclusively on Nasdaq at USD 3.92 (–36.8%). On May 28, 2025, the company applied to delist from the Canadian Securities Exchange, effective post-close on June 2. IMC has exited Canadian operations to reallocate capital toward its Israeli and German markets. Earnings are scheduled for August 12–18, 2025.